Navigation Links
COLD-FX(R) Receives Highest Sports Certification in North America

Vancouver Organizing Committee for the 2010 Olympic and Paralympic Winter Games and CCES Acknowledge NSF International's Certified for Sport(TM) Certification as Important Milestone

ANN ARBOR, Mich. and EDMONTON, Alberta, Sept. 14 /PRNewswire-USNewswire/ -- Afexa Life Sciences Inc. ("Afexa") (TSX:FXA) today announced that COLD-FX(R) has received the highest sports certification in North America from the leading product safety and banned substances testing body for elite athletes.

The certification comes from NSF International, a U.S.-based, not-for-profit public health and safety organization, under its NSF Certified for Sport(TM) program. NSF's special certification program is used by the Vancouver Organizing Committee for the 2010 Olympic and Paralympic Winter Games (VANOC), the Canadian Centre for Ethics in Sport (CCES), the National Football League (NFL), Major League Baseball (MLB), the Ladies Professional Golf Association (LPGA) and the PGA.

Ed Wyszumiala, General Manager of NSF's Dietary Supplements Certification programs says, "COLD-FX received this sports certification after undergoing a rigorous testing program, which included a series of Good Manufacturing Practices (GMP) facility audits, label claim testing/verification and banned substance testing for over 130 analytes. All of these requirements were met in addition to meeting the requirements in NSF/ANSI* Standard 173, which is the only accredited American National Standard for dietary supplements and ingredients."

With ongoing monitoring and testing, athletes can feel confident that COLD-FX has met and will continue to meet all of NSF's certification requirements to ensure the product is free of banned substances.

"We congratulate COLD-FX on achieving this important certification, and we are pleased we can showcase this product to the world as an example of Canadian scientific ingenuity and innovation," says VANOC Chief Medical Officer Dr. Jack Taunton. "Afexa has done praiseworthy and unique research in the field of cold and flu medicine and will help keep our workforce healthy during the Games as we prepare to host the world in 2010."

Earlier this year, COLD-FX was chosen as the Official Cold and Flu Remedy of the Vancouver 2010 Olympic and Paralympic Winter Games. COLD-FX's high standards for safety and efficacy were key factors in it being selected for this important recognition.

CCES - the body which administers Canada's doping control program - praised COLD-FX's certification. Paul Melia, CEO of CCES says, "The certification demonstrates Afexa's leadership and corporate responsibility to Canadian athletes. I hope this will set an example for other supplement and sports nutrition companies in Canada."

Afexa's Chief Scientific Officer Dr. Jacqueline Shan says, "COLD-FX has a long history of use by amateur and professional athletes in Canada due to its effectiveness and safety backed by a decade of science and clinical trials. Our ChemBioPrint(R) standardization technology ensures batch-to-batch consistency. We are pleased that NSF Certification supports the results of a ground-breaking clinical trial conducted by a team of sports researchers at the University of Manitoba in 2002. It concluded that COLD-FX does not contain any International Olympic Committee (IOC)-banned or restricted substances and does not produce or induce banned substances in the body. The results were published in a leading peer-reviewed sports/medicine journal in 2004. Afexa is committed to developing products that are both safe and effective for elite athletes as well as the general public."

COLD-FX is widely used by Canadian Olympians and was first recommended to elite athletes by the Canadian Sport Centre Calgary in 2003. Earlier this year, all of the Canadian Sport Centres decided to recommend it to their athletes to help keep them in top health in this particularly challenging flu season.

Canadian Sport Centre Calgary President Dale Henwood says, "This certification is an important achievement. It provides additional confirmation for athletes who regard COLD-FX as a key part of their health regimen." Afexa is providing COLD-FX to 1,500 athletes, coaches, trainers and support staff at sport centres in seven provinces where the country's elite athletes train, including those preparing for the 2010 Winter Games.

Olympic Gold Medalist Clara Hughes says, "Many of my teammates and I rely upon it. I've gone through dozens and dozens of tests since I started taking COLD-FX over six years ago, and each time they come back negative for banned substances. NSF Certification is just further confirmation that athletes can take it without having to worry."

COLD-FX will be the exclusive cold and flu remedy available at general stores within the Olympic and Paralympic Villages in Vancouver and Whistler. VANOC has arranged with Afexa to make COLD-FX available to close to 40,000 volunteers, staff and media during the 2010 Winter Games.

*American National Standards Institute

To view the entire news release, please visit

    Greta Houlahan
    NSF International

    Warren Michaels
    Afexa Life Sciences Inc.

SOURCE NSF International
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Project Lifesaver International Receives Federal Assistance for the Missing Alzheimers Patient Assistance Program
2. RZN Nutraceuticals Receives United States Patent & Trademark Office Notice of Allowance for Proprietary HerbaZorb(TM) Absorption and Delivery System Technology Used in Popular Arthri-Zen Relief(R) and Migra-Zen Relief PLUS(R) Products
3. UM receives grant to support graduate students in the family nurse practitioner program
4. Par Pharmaceutical Receives Final Approval To Market Generic Starlix(R)
5. CBM-US Receives $3 Million Grant To Fund HIV/AIDS Prevention and Care Efforts in Africa
6. Solos Endoscopy, Inc. Receives Purchase Order from One of the Major Healthcare Systems in Missouri
7. Ascenta Therapeutics Receives Clearance to Initiate Clinical Trials With AT-406
8. Isis Receives Notice of Allowance That Expands the Scope of Key RNA Therapeutic Patents for Single-Stranded RNAi Technology
9. Childrens Hospital receives federal contract to study antibiotic use in children with UTIs
10. Emdeon Receives EHNAC Healthcare Network Re-accreditation
11. ARUP Laboratories Scientist Tanya Sandrock Receives NIH Grant to Search for Additional HIV Therapies
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... It’s inevitable that everyone ... member, close friend, or animal pass away, death lives among us. It is your ... Coming from a family of 11 children, author T Sky understands that she may ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... announce the speakers for “Value-Based Payer-Provider Partnerships: Three Case Studies,” an upcoming ... value-based care arrangements: Essentia Health and UCare, MissionPoint Health Partners, and Intel ...
(Date:11/30/2015)... IL (PRWEB) , ... November 30, 2015 , ... The ... an emerging pharmaceutical company. Because it is so important to this key industry segment, ... Factors in your IND Filing” on December 4th at 11am EST. , Federal law ...
(Date:11/30/2015)... ... November 30, 2015 , ... Insightra Medical, Inc. ... Surgical Mesh technology for soft tissue repair in the US via Insightra’s national ... resorbable surgical mesh intended to support and reinforce soft tissue for 6-9 months ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... & Laser Center is one of a select few plastic surgeons in the ... non-surgical fat removal. , SculpSure™ is the world’s first heat-induced laser treatment for ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... -- Booth #4303 – The Imaging Components business of Varian ... array of products in a new booth (#4303) at the ... America in Chicago this ... components "At the Heart of Imaging." Products will include a ... Claymount brand, and computer-aided diagnostic software from MeVis as well ...
(Date:11/30/2015)... -- Hanger, Inc. (NYSE: HGR ) (the "Company") today ... its previously announced consent solicitation (as amended and restated, ... amount 7⅛% Senior Notes due 2018 (the "Notes") to ... pursuant to the Consent Solicitation, (ii) the proposed increased ... date of the Consent Solicitation.    ...
(Date:11/30/2015)... , Nov. 30, 2015   VolitionRx Limited (NYSE ... diagnostic tests for a broad range of cancer types and ... LD Micro Conference, which will be held December 1 - 3 ... from VolitionRx will be David Kratochvil , Chief Financial ... of Investor Relations. ® blood-based tests for ...
Breaking Medicine Technology: